Suppr超能文献

重组人细胞珠蛋白治疗酒精性脂肪性肝病中差异表达蛋白质的生物信息学分析

Bioinformatics analysis of differentially expressed proteins in alcoholic fatty liver disease treated with recombinant human cytoglobin.

作者信息

Zhang Zi-Rong, Yang Zheng-Gen, Xu Yan-Mei, Wang Zhe-Yan, Wen Jian, Chen Bo-Hong, Wang Ping, Wei Wei, Li Zhen, Dong Wen-Qi

机构信息

Department of Biopharmacy, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.

Guangzhou Koncen BioScience Co., Ltd., Guangzhou, Guangdong 510530, P.R. China.

出版信息

Mol Med Rep. 2021 Apr;23(4). doi: 10.3892/mmr.2021.11929. Epub 2021 Mar 2.

Abstract

Cytoglobin (Cygb) is a globin molecule that is ubiquitously expressed in all tissues and has a protective role under oxidative stress. It has also been demonstrated to be effective in the treatment of alcoholic fatty liver disease (AFLD). In order to study the molecular mechanisms underlying its beneficial effects for the treatment of alcoholic liver, two‑dimensional electrophoresis and mass spectrometric analysis were performed on serum and liver tissues from an rat model of AFLD. A total of 26 differentially expressed proteins were identified in the serum and 20 differentially expressed proteins were identified in liver specimens. Using online bioinformatics tools, it was indicated that these differentially expressed proteins were primarily associated with pathways including binding and uptake of ligands by scavenger receptors, response to corticosteroid, plasma lipoprotein remodeling, regulation of complement cascade, hydrogen peroxide catabolic process, as well as response to nutrient and monosaccharide. The present results suggested that recombinant human Cygb exerts its role in the treatment of AFLD primarily through affecting nutrient metabolism, monocarboxylic acid biosynthesis, regulation of glutathione expression, plasma lipoprotein remodeling and removal of metabolic waste from the blood.

摘要

细胞珠蛋白(Cygb)是一种在所有组织中普遍表达的珠蛋白分子,在氧化应激下具有保护作用。它也已被证明在治疗酒精性脂肪肝病(AFLD)方面有效。为了研究其治疗酒精性肝病有益作用的分子机制,对AFLD大鼠模型的血清和肝组织进行了二维电泳和质谱分析。在血清中总共鉴定出26种差异表达蛋白,在肝脏标本中鉴定出20种差异表达蛋白。使用在线生物信息学工具表明,这些差异表达蛋白主要与包括清道夫受体对配体的结合和摄取、对皮质类固醇的反应、血浆脂蛋白重塑、补体级联调节、过氧化氢分解代谢过程以及对营养物和单糖的反应等途径相关。目前的结果表明,重组人Cygb主要通过影响营养代谢、单羧酸生物合成、谷胱甘肽表达调节、血浆脂蛋白重塑以及从血液中清除代谢废物来发挥其在治疗AFLD中的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5fa/7930997/30f8d3b2af93/mmr-23-04-11929-g00.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验